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Past and recent findings on tumor heterogeneity have led clinicians and researchers to broadly define cancer
development as an evolving process. This evolutionary model of tumorigenesis has largely been shaped by seminal
reports of fitness-promoting mutations conferring a malignant cellular phenotype. Despite the major clinical and
intellectual advances that have resulted from studying heritable heterogeneity, it has long been overlooked that
compositional tumor heterogeneity and tumor microenvironment (TME)-induced selection pressures drive tumor
evolution, significantly contributing to tumor development and outcomes of clinical cancer treatment. In this
review, we seek to summarize major milestones in tumor evolution, identify key aspects of tumor heterogeneity in
a TME-dependent evolutionary context, and provide insights on the clinical challenges facing researchers and
clinicians alike.
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Cancer has been traditionally typified by a stepwise
accumulation of mutations in key oncogenes and tumor
suppressors [1]. For decades, accumulation of these
traits in somatic cells has been considered as the foun-
dation of a developmental model of tumor progression
where cells transition from a normal, healthy state to
pre-malignant, malignant, and migratory phenotypes [1].
Consequently, tumors display distinguishing traits, de-
fined as hallmarks of cancer [2], that demarcate malig-
nant cells from normal cells [3].
Meanwhile, tumors are often described as heteroge-
neous, owing to the intricate genetic diversity and as-
sorted morphological phenotypes they embody [2].
Intratumor heterogeneity specifically refers to hetero-
geneity within a tumor, while intertumor heterogeneity
refers to heterogeneity across several different tumors
[3]. The current view of tumor heterogeneity recognizes
basic principles of Darwinian evolution at the core of
neoplastic development and outgrowth: a single somatic
cell with a heritable fitness-promoting mutation prolifer-
ates, conferring a survival advantage that allows cells to
outlast the less ‘fit’ cells [3,4]. Natural selection leads to
sequential waves of clonal expansion, resulting in various* Correspondence: szhang8@nd.edu
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tion, and invasion [5]. While similarities promoting tumor
survival are maintained among subclones, changes in the
local tumor microenvironment (TME) further influence
genetic divergence and phenotypic outcomes [5]. This
rigorous fitness test promotes genomic instability, thus
contributing to the vast heterogeneity observed in cancer
genomes [2,6,7].
Advances in next-generation sequencing techniques
and the inception of The Cancer Genome Atlas (TCGA)
have revealed extensive heterogeneity at the molecular
level [8]. However, scientists and physicians remain per-
plexed by the origins of cancer heterogeneity and its
mechanistic and clinical implications. Understanding
tumor heterogeneity is the first of many important steps
toward improving both the clinical management and
treatment of cancer.
In this review, we will revisit the key milestones in
tumor evolution, highlight the evolving concepts of
tumor heterogeneity, and provide insight on the clinical
challenges facing researchers and clinicians alike.Major milestones in tumor evolution
Three hundred years after the invention of the micro-
scope, concurrent with the dawn of Darwinian evolution,
German physiologist Johannes Muller and his assistants
applied microscopy to human tumor samples in 1833.entral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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collected with the naked eye, leaving layers of critical in-
formation untapped. Applying methods used by botanists
and plant physiologists, Muller transformed pathology and
modern medicine with his monograph on cancer. This led
to his conjecture that tumors are composed of new cells
within a diseased organ. Muller and colleagues morpho-
logically distinguished carcinoma subtypes within a single
tumor and noted variation among tumor-adjacent con-
nective tissues, detailing the vast heterogeneity observed.
It was Muller’s student, famed pathologist Rudolf Virchow,
who later determined that all tumors derive from normal
cells. Muller and Virchow transformed modern medicine
not just by inventing the field of pathology, but also by
recording some of the earliest evidence that tumors are
heterogeneous [9,10].
All tumors possess some form of somatic mutation,
and our current understanding of tumor heterogeneity is
built upon the principle that acquired mutations are her-
itable [11]. Essential to this point is Theodor Boveri’s
keen observation at the beginning of the twentieth cen-
tury that aberrant mitoses are associated with malignant
tumors and his findings on inheritance factors [12].
Boveri traced the fate of each cell and found that cells
with different chromosome combinations were pheno-
typically dissimilar, which led to two main conclusions:
(1) chromosomes transmit different inheritance factors
and (2) unequal chromosome distribution is detrimen-
tal to normal development [13]. Decades later, key re-
ports by David Hungerford, Peter Nowell, and Janet
Rowley further substantiated Boveri’s hypothesis, be-
coming one of the most important milestones in cancer
research [14,15]. In 1976, Nowell published a now in-
famous paper depicting a working model for tumor
evolution [5]. Among several persuasive thoughts, Nowell
described a cancer progression model where major gen-
etic errors drive natural selection of cells with improved
fitness in response to intrinsic and extrinsic pressures.
This ecological view of tumor development hasFigure 1 Timeline of the evolving concepts of tumor heterogeneity.captivated researchers and become a core concept in
today’s cancer research (Figure 1).
Classic view: heritable tumor heterogeneity
Genetic heterogeneity
Genetic heterogeneity of tumors is rooted in one of the
key hallmarks of cancer: genetic instability [2]. Several
mechanisms are in place in normal cells that protect
against chromosome and nucleotide damage by prevent-
ing DNA replication until damage is repaired; however,
genes controlling these critical checkpoints (e.g. p53) are
often perturbed in cancer cells [16]. Genetic instability in
cancer has been demonstrated at both the nucleotide level
in point mutations and chromosome level in transloca-
tions, deletions, amplifications, and complete chromosome
aneuploidy [17]. One of the major genetic dysfunctions
initiating cancer is telomere crisis, which is characterized
by extensive cell death and concomitant cytogenetic ab-
normalities [18]. Telomere crisis results in end-to-end
chromosome fusion passed on to daughter cells that sub-
sequently harbor the same chromosome rearrangement
patterns and dsDNA fracture [19]. It is surmised that can-
cer initiation progresses toward malignancy once the fit-
test clone survives extreme chromosomal rearrangement
events in the absence of protective telomeres [20]. As this
cell population expands, negative selection occurs against
clones with detrimental rearrangements. In many circum-
stances, it is probable that a multitude of cells survive,
each with a unique genome, resulting in a high degree of
intratumor genetic heterogeneity [3].
Tumor cells undergo a series of genetic events that
contribute to genomic instability throughout tumor pro-
gression (Figure 2A). However, the specific mechanisms
and precise order in which they occur have yet to be elu-
cidated [21]. Studies have pursued these mechanisms
and found that the rate at which mutations occur in
somatic cells is insufficient to cause the striking number
of mutations present in cancer genomes. Over the past
few decades, a ‘mutator’ hypothesis tumor evolution has
Figure 2 Tumor evolution and compositional heterogeneity. A, Evolution drives heritable heterogeneity and subsequent outgrowth of
malignant clones. Selection pressures from the local microenvironment (e.g. hypoxia, secretion of growth-inhibiting factors, chemotherapeutic agents,
etc.) challenge tumor cell survival, often resulting in cell death in early cancer initiation. In order to survive these in a given tissue niche, cancer cells
must acquire mutations that promote survival and tumor formation with regard to spatiotemporal context. Robust cells capable of surviving multiple
selection events acquire proliferative advantages, eventually resulting in tumor progression and evidence of genetic heterogeneity within a tumor.
B, Snapshots of natural selection events within the TME paint a heterogeneous portrait of tumor composition in a spatial context. The TME refers to
both the tumor and its local environment of diverse resident and migratory cell types. 1) Infiltrated immune cells shape the tumor development; 2)
Tumor stromal cells interact with tumor cells and change the local cancer stem cell niche; 3) Bi-directional plasticity between stem-like cancer cells and
tumor cells. 4) Disseminated tumor cells.
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ized by genomic instability drives multi-step carcinogenesis
and explaining the mutation rate discrepancy observed in
normal and malignant cells [22]. This concept was initiallydescribed in Nowell’s paper where he attributes the high
number of mutations in cancer genomes to waves of clonal
selection [5,23]. Studies in bacteria and yeast imply muta-
tor mutations confer a selective growth advantage on cells
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mutator hypothesis speculates that a small number of
‘driver’ alterations exist and, once acquired by somatic mu-
tation, confer the cancer phenotype; however, seemingly
insignificant ‘passenger’ mutations result via mechanisms
yet to be elucidated [26]. McFarland et al. challenged this
with stochastic simulation of tumor evolution and rea-
soned that, though individually weak, the cooperative bur-
den of small-scale accumulated passenger mutations has a
present role in tumor progression, and may be the cause
for complex oncological events that remain unanswered by
the driver-centric model [27].
Genomic analyses have provided evidence that drastic
rearrangement events such as aneuploidy, a defining fea-
ture of genetic instability and cancer, and chromothripsis
drive cancer progression [28]. Despite relative detection
ease, the precise evolutionary advantage of aneuploidy in
cancer progression remains unclear. Studies in C. albi-
cans suggest aneuploidy promotes fitness throughout
drug resistance evolution, similar to cancer, contrasting
S. cerevisiae, which displays growth deficits as a result of
aneuploidy [29]. Others have reported that S. cerevisiae
diploids exhibit an increased number aneuploidy events
under strong selection pressure [30]. Comparable to
yeast, it is possible that aneuploidy occurs when survival
is most threatened and the need to employ a rapid re-
arrangement mechanism is highest.
In the past 10 years, genetic sequencing data from in-
dependent laboratories and collective efforts from The
Cancer Genome Atlas (TCGA) and ICGC (International
Cancer Genome Consortium) produced global genetic
profiles of different types of cancer [31-36]. As depicted
in Figure 1, these milestones studies provides a new
framework for future omic analyses based personalized
cancer therapy.
Epigenetic heterogeneity
The epigenome is defined as the whole suite of epigenetic
factors that regulate expression of the genome and includes
both heritable and non-heritable cellular changes that have
been shown to contribute to tumor development and pro-
gression [37]. Temporal and spatial gene regulation has
been recently appreciated in cancer biology. By far the
most intensively studied heritable epigenetic alteration is
DNA methylation, pioneered by Feinberg and Vogelstein
[38]. Decreased methylation of satellite DNA has been as-
sociated with abnormal chromosome rearrangement and
aneuploidy [38,39]. Furthermore, tumor-specific aberra-
tions in DNA methylation of tumor suppressor promoter
regions have been well characterized [40].
Next generation sequencing techniques have advanced
the current understanding of the epigenome and further
complicated the current concept of tumor heterogeneity.
Chromatin immunoprecipitation followed by sequencing(ChIP-seq) offers single nucleotide resolution, an unlimited
dynamic range, and the capacity to multiplex samples [41].
Recently, ChIP-seq has been implemented in the identifica-
tion of long-range epigenetic activation (LREA) in DNA
regions containing microRNAs, oncogenes, and cancer
biomarker genes, where Bert et al. found that epigenetic al-
terations can be influenced by adjacent genes [42]. Another
recent study by Vanharanta et al. applied ChIP-seq to show
epigenetic enabling of the von Hippel-Lindau (VHL) tumor
suppressor activation of hypoxia inducible factors (HIFs)
for metastasis [43]. More over, Hansen et al. recently
reported an increased variance of putative CpG sites in
tumor cells compared to normal cells across several types
of cancer [44]. Significant loss of methylation stability block
regions of DNA implied that tumor heterogeneity might
potentially evolved from loss of epigenetic stability of well-
defined genomic domains [44].
Tumor heterogeneity: the origin of tumor species
Cancer evolution and heterogeneity is a long debated
subject that questions the tumor origin. Borrowing prin-
ciples of evolution and biodiversity, scientists have rea-
soned that tumors originate in stem cell populations, as
the innate longevity of stem cells increases the chance of
acquiring harmful mutations [45]. Increasing evidence
from studies on hematopoietic cancers [46], breast can-
cers [47], and brain cancers [48] has led researchers to
believe that cellular heterogeneity of the tumor has been
largely attributed to clonal expansion of putative cancer
stem cells (CSCs). The CSC model addresses two key
components of tumorigenesis: tumor origin and tumor
capacity. CSCs are defined as cells that can both self-
renew and give rise to the various cell types within a
tumor [49]. Central to this hypothesis is the notion that
tumors originate in tissue stem cells (i.e. a particular
progenitor population within the tissue) as a result of
disordered self-renewal mechanisms [45]. Accordingly,
tumor cells display a hierarchical order of potential in
which cells of the highest order possess self-renewal and
simultaneous multi-lineage differentiation capacity [50].
Early clonogenic and tumor sphere forming assays
showed evidence of stem like cells in heterogeneous tu-
mors; however, these in vitro assays are not a true assess-
ment of self-renewal capacity [45]. Further confirmation of
a CSC population was the clinical observation that certain
leukemia displayed poorly proliferative progenitor popula-
tion [51]. Moreover, John Dick and colleagues performed
groundbreaking studies that led to the identification and
proposition of a CSC population in acute myeloid leukemia
(AML) [52]. Lapidot et al. isolated the reputed CSC popu-
lation using classical stem cell markers from patient per-
ipheral blood and demonstrated that a subpopulation of
progenitor cells could recapitulate AML in SCID mice and
displayed potential for self-renewal. These findings formed
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further identification of cancer stem-like cells tumor initi-
ating cells in breast cancer and brain tumors [45].
The traditional CSC hypothesis implies that cellular
hierarchies exist in tissues with stem cells (in normal tis-
sues) or CSC (in tumors) at their respective apices [53].
Chaffer and colleagues challenged the traditional CSC hy-
pothesis in their demonstration that human mammary
epithelial cells can revert to a stem-like state under certain
conditions rather than adhering to unidirectional differen-
tiation hierarchy [54]. This study and others, while exten-
sively debated, characterize the dynamic phenotypic
changes tumor cells undergo to promote survival, migra-
tion, and proliferation at secondary sites [55]. Transient
phenotypic shifts such as the epithelial-mesenchymal
(EMT) and mesenchymal-epithelial transitions (MET), are
understood as conversions facilitating cell plasticity, but
have recently gained appreciation as events underlying
compositional tumor heterogeneity (Figure 2B) in unison
with the findings discussed below by Wang and colleagues
[56] and Chaffer and colleagues [53].
Tumor microenvironment-driven transient
compositional tumor heterogeneity
It is abundantly clear that the evolutionary selection of fit
clones is a system-wide process that occurs in a dynamic
tissue milieu termed the tumor microenvironment (TME)
[57]. Bissell and colleagues pioneered the concept [58] that
a progressively remodeled TME influences both genetic
and compositional heterogeneity [59]. Increasing evidence
demonstrates that changes in the tumor ecosystem drive
compositional tumor heterogeneity. Hoadley et al. com-
piled an extensive molecular taxonomy report across sev-
eral different cancer types where tissue of origin provided
the strongest identification signal [60]. This key result is
not surprising, as epithelial-adjacent stroma could differ
from connective, nervous, and muscular stroma. A study
by Wang et al. provides direct evidence that the tumor
stroma harbors a deregulated ECM that promotes malig-
nancy and intratumoral heterogeneity in mammary gland
models [56]. Michor and Weaver claim these findings as
further evidence of neo-Darwinian evolution in cancer
[61]. These reports question the current tumor cell centric
model of plasticity by implying cancer cells posses a dy-
namic, almost sentient nature.
TME-imposed heterogeneity derives from CSCs
Stem cell self-renewal and differentiation is dictated by
the microenvironment, or stem cell niche. Normal stem
cell niches are generally located in hypoxic tissue niches
(e.g. mammary stem cells in the basal compartment of
the mammary gland) that promote the stem cell pheno-
type. Poorly vascularized tumors contain hypoxic regions
with undifferentiated ‘stem-like’ tumor cells that surviveunder control of HIFs [62]. Yeung et al. used 3D cell cul-
ture to demonstrate that hypoxia inhibits differentiation of
colon cancer cells and maintains a stem-like phenotype
[63]. In addition, the putative stem cell niche constitutes
numerous cross-talking stromal cells. Vermeulen et al.
demonstrated that myofibroblasts secrete factors that
maintain the CSC population in colon cancer cell culture
models [64]. They showed stromal cells impose a CSC
phenotype on differentiated cancer cells, justifying the
transient morphological heterogeneity observed in cancer.
Recently, Chaffer et al. reported basal breast cancers cells
retain the ZEB1 promoter in a configuration allowing
ample response to environmental signals [53]. These
results corroborate a cancer cell plasticity model where
conversions occur between various cell states with fluctu-
ating tumorigenic capacities. These recent findings, in
summary, mark the beginning of a momentous conceptual
shift in the CSC hypothesis and tumor evolution.
Infiltrated stromal cells and tumor heterogeneity
Studies on deregulation of the tumor secretome provide
compelling evidence for the TME as a major contributor
to compositional tumor heterogeneity. Substantial evi-
dence supporting a role for inflammation in cancer pro-
gression has been reported in the last decade and is
commonly accepted as a hallmark characteristic of the
TME [65]. One of the major mechanisms of tumorigenesis
is production of self-sustaining inflammatory cytokines
(e.g. IL-1, IL-6, TNF) by pre-malignant cells, resulting in
extensive recruitment of diverse immune cells and chal-
lenging cellular fitness by altering niche dynamics [66].
Constitutive activation of NF-κB impedes activity of the
tumor suppressor p53, a prominent hub in DNA-induced
cellular stress networks and regulator of cellular senes-
cence [67]. Reciprocally, tumor development conditions
the surrounding TME. Lujambio et al. recently demon-
strated that, in the context of chronic liver inflammation,
depletion of a p53-dependent senescence program in
tumor cells results in increased cirrhosis and fibrosis that
promotes adjacent epithelial malignant transformation
and transient intratumoral heterogeneity [68].
The collective interplay between the CSCs and the
TME results in compositional intratumor heterogeneity
(Figure 2B). However, the in-depth molecular mecha-
nisms of this dynamic interplay along with functional
consequences of compositional heterogeneity have yet to
be revealed.
Final thoughts: the ugly truth of tumor heterogeneity
The dawning of the age of ‘omics’ brought with it great
hope for discovery and validation of novel biomarkers,
relevant drug targets, and disease-specific signatures
[69]. Powerful sequencing technologies have painted a
daunting portrait of tumor evolution [11,32,34,70] and
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the only hurdle to overcome: recent advances in single
cell RNA-seq also depicted epigenetically regulated tran-
scriptome heterogeneity in primary glioblastoma [71].
The current paradigm of personalized medicine involves
tailoring therapy around profiled signaling variations be-
tween tumors [72]. With significant strides made in un-
derstanding tumor heterogeneity in recent years, it is
unsettling that the conventional treatment strategy is to
profile the tumor based on the most prevalent clone at
the time of diagnosis or relapse, ignoring the ugly truth
that intratumoral heterogeneity promotes the evolution-
ary nature of tumor development.
Careful consideration of the complete tumor context is
essential to understanding and developing more effective
personalized treatments that address tumor heterogeneity.
The first challenge is whether genetic and compositional
profiling of multifocal tumors of monoclonal origin dis-
playing intrafocal heterogeneity can be effectively manage
[73]. Multifocality occurs in 30% of breast cancer cases and
50-76% of prostate cancer cases, among others [74,75].
Current reports suggest directing treatment at the domin-
ant foci largely underestimates malignant potential, further
highlighting the need to better understand each patient’s
genetic and compositional tumor heterogeneity [75]. To
tackle this challenge, Fujii et al. recently generated a com-
puter model to further study multifocal prostate cancer
based on data obtained from 152 human prostatectomy
specimens evaluated by DNA microarray analysis, where
they demonstrated heterogeneous individual foci with a
common clonal precursor [76]. Beckman et al. reported
another mathematical model of personalized treatment
that integrates dynamics of evolutionary genetics into ana-
lysis and treatment design. Their analyses of hypothetical
cases as well as a simulated clinical trial of over 3 million
qualified ‘patients’ showed that augmented and, occasion-
ally counterintuitive, nonstandard treatment strategies may
lead to improved patient survival compared with the
current model of personalized medicine [72].
A number of new concepts have emerged in recent
years. The concept of intratumoral cell competition
among heterogeneous clones reshaped our classic hier-
archical view of heterogeneity and potentially can be
exploited as therapeutic entry points in eradicating multi-
focal cancers [77]. Cleary et al. showed evidence of two
genetically distinct tumor cell subclones in communica-
tion to maintain the tumor population [78]. This leading-
edge report sheds light on how diverse tumor cell popula-
tions persist despite clonal selection, often thwarting
current clinical therapies. In addition, many studies have
explored how heterogeneity within a specific type of can-
cer promotes self-seeding and metastatic outgrowth.
Campbell et al. employed advanced genomics techniques
to further understand the underlying mechanisms drivingpancreatic cancer progression and metastasis. Despite
showing vast genetic diversity, the authors were able to elu-
cidate a distinct pattern of genomic instability [79]. More-
over, to better stratify the clinical cancer subtypes, Gatza
et al. recently used integrated genomics to characterize the
functional role of key genetic driver mutations in luminal
breast cancer and correlated specific genetic signatures with
poor prognosis [80]. Although the genetic diversity re-
ported in findings is daunting, these results represent tre-
mendous strides forward for potential identification of
therapeutic targets for diseases with few clinical options.
With massive omics data generated from The Cancer
Genome Atlas (TCGA), various algorithms and tools for
recognition of activated and altered pathways exist for inte-
grative analysis of two or more types of omics data and are
rapidly proving worthwhile [81]. Notably, Kristensen et al.
used Pathway Recognition Algorithm using Data Integra-
tion on Genomic Models (PARADIGM) analyses based on
copy number alterations (CNAs) and mRNA expression of
data from the MicroMetastases Project (MicMa) cohort to
show that integrated analysis of DNA copy number alter-
ation and mRNA expression leads to improved prognostic
discrimination of patients compared to separate analysis of
any other molecular levels [82]. Five distinct clusters of in-
vasive breast cancer were identified and found to uniformly
express a chronic inflammatory signature [82]. Similarly,
The Physical Sciences-Oncology Network completed an-
other project implementing integrated omics analyses to
characterize basic breast cancer research models. Over
twenty labs designed a series of multidisciplinary com-
parative studies on two cell lines: MCF10A (non-tumori-
genic breast cells) and metastatic breast cancer cells
(MDA-MB-231 cell line). Comprehensive network signa-
tures for motility, morphology, and cellular stress were
constructed from transcriptomics and proteomics data
from each cell line [83]. Among their results was the find-
ing that integrin-β4 is a common node between the non-
tumorigenic and metastatic breast cancer cell lines [83].
Conclusions
Taken together, future integrated omics analyses with con-
sideration of compositional heterogeneity inferred by
interplay between intratumoral subclones and TME will
allow us to identify more robust biomarkers and devise
therapeutic strategies for cancer treatment, such as stag-
gering targeted therapies to keep selection pressures min-
imal [84]. Mapping the evolutionary roots of tumor
heterogeneity will be the foundation of personalized medi-
cine in the oncology clinic in the foreseeable future.
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